# A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

> **NCT02413827** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celldex Therapeutics** · enrollment: 9 (actual)

## Conditions studied

- Unresectable Stage III or Stage IV Melanoma

## Interventions

- **DRUG:** Combination of varlilumab and ipilimumab
- **DRUG:** Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC

## Key facts

- **NCT ID:** NCT02413827
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2016-11-02
- **Final completion:** 2016-11-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Feasibility concerns due to changes in standard of care
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413827, "A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02413827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*